1. Home
  2. SLN vs MLP Comparison

SLN vs MLP Comparison

Compare SLN & MLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Silence Therapeutics Plc American Depository Share

SLN

Silence Therapeutics Plc American Depository Share

HOLD

Current Price

$13.87

Market Cap

300.9M

Sector

Health Care

ML Signal

HOLD

MLP

Maui Land & Pineapple Company Inc.

HOLD

Current Price

$15.94

Market Cap

341.9M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLN
MLP
Founded
1994
1909
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
300.9M
341.9M
IPO Year
2010
2010

Fundamental Metrics

Financial Performance
Metric
SLN
MLP
Price
$13.87
$15.94
Analyst Decision
Buy
Analyst Count
5
0
Target Price
$42.60
N/A
AVG Volume (30 Days)
1.1M
14.5K
Earning Date
05-07-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$559,000.00
$19,457,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
68.24
52 Week Low
$4.19
$13.84
52 Week High
$17.58
$20.34

Technical Indicators

Market Signals
Indicator
SLN
MLP
Relative Strength Index (RSI) 69.56 38.87
Support Level $5.28 $15.23
Resistance Level N/A $16.31
Average True Range (ATR) 1.12 0.66
MACD 0.29 -0.16
Stochastic Oscillator 58.02 2.87

Price Performance

Historical Comparison
SLN
MLP

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

About MLP Maui Land & Pineapple Company Inc.

Maui Land & Pineapple Co Inc is a landholding and operating parent company that owns land and commercial property on the island of Maui, Hawaii. The Company puts its assets into productive use by planning, managing, developing, and selling residential, resort, commercial, agricultural, and industrial real estate. Its segments include land development and sales, which cover land planning, entitlement, development, construction, and sales of land assets; leasing, which generates revenue from real property leasing, license fees and royalties, and includes maintenance of real estate assets, conservation activities, and management of water systems in West and Upcountry Maui; and resort amenities, which include a membership program offering benefits within the Kapalua Resort.

Share on Social Networks: